Somaxon starts insomnia Phase III

Somaxon (San Diego, Calif.) started a double-blind, placebo-controlled, U.S. Phase III trial of Silenor doxepin to treat primary, chronic insomnia in about 240 adults. The primary endpoint is wake aft...